Response to Therapy
After ablation (cavo-tricuspid isthmus or CTI ablation) for AFL,
~60% of patients will exhibit AF over the subsequent 5
years25. Stratifying those patients presenting with
AFL who are likely to develop AF has management implications with
regards to ongoing arrhythmia surveillance, long-term anticoagulation
and index ablation strategy. It has been suggested in some patients who
present with AFL alone, a combined AFL/prophylactic AF ablation strategy
is warranted26. To date, the clinical utility of
polygenic risk scores in AF management has been limited27. Our data suggest a potential use case for an AF
GRS in clinical practice. AF polygenic risk appears to identify those
patients presenting with AFL where future AF is likely.